A phase Ib open-label, escalating repeat-dose trial of bavituximab (chimeric anti-phosphatidylserine monoclonal antibody) in patients with chronic hepatitis C

Trial Profile

A phase Ib open-label, escalating repeat-dose trial of bavituximab (chimeric anti-phosphatidylserine monoclonal antibody) in patients with chronic hepatitis C

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2007

At a glance

  • Drugs Bavituximab (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Peregrine Pharmaceuticals
  • Most Recent Events

    • 17 May 2007 Status changed from in progress to completed.
    • 14 Feb 2007 Interim results have been reported.
    • 12 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top